4fqx Citations

Crystal Structure of the HLA-DM-HLA-DR1 Complex Defines Mechanisms for Rapid Peptide Selection.

Abstract

HLA-DR molecules bind microbial peptides in an endosomal compartment and present them on the cell surface for CD4 T cell surveillance. HLA-DM plays a critical role in the endosomal peptide selection process. The structure of the HLA-DM-HLA-DR complex shows major rearrangements of the HLA-DR peptide-binding groove. Flipping of a tryptophan away from the HLA-DR1 P1 pocket enables major conformational changes that position hydrophobic HLA-DR residues into the P1 pocket. These conformational changes accelerate peptide dissociation and stabilize the empty HLA-DR peptide-binding groove. Initially, incoming peptides have access to only part of the HLA-DR groove and need to compete with HLA-DR residues for access to the P2 site and the hydrophobic P1 pocket. This energetic barrier creates a rapid and stringent selection process for the highest-affinity binders. Insertion of peptide residues into the P2 and P1 sites reverses the conformational changes, terminating selection through DM dissociation.

Reviews - 4fqx mentioned but not cited (1)



Reviews citing this publication (21)

  1. Proofreading of Peptide-MHC Complexes through Dynamic Multivalent Interactions. Thomas C, Tampé R. Front Immunol 8 65 (2017)
  2. Peptide and Peptide-Dependent Motions in MHC Proteins: Immunological Implications and Biophysical Underpinnings. Ayres CM, Corcelli SA, Baker BM. Front Immunol 8 935 (2017)
  3. Introduction: MHC/KIR and governance of specificity. Kelly A, Trowsdale J. Immunogenetics 69 481-488 (2017)
  4. The Other Function: Class II-Restricted Antigen Presentation by B Cells. Adler LN, Jiang W, Bhamidipati K, Millican M, Macaubas C, Hung SC, Mellins ED. Front Immunol 8 319 (2017)
  5. Major Histocompatibility Complex (MHC) Class I and MHC Class II Proteins: Conformational Plasticity in Antigen Presentation. Wieczorek M, Abualrous ET, Sticht J, Álvaro-Benito M, Stolzenberg S, Noé F, Freund C. Front Immunol 8 292 (2017)
  6. Variations in MHC Class II Antigen Processing and Presentation in Health and Disease. Unanue ER, Turk V, Neefjes J. Annu. Rev. Immunol. 34 265-297 (2016)
  7. Present Yourself! By MHC Class I and MHC Class II Molecules. Rock KL, Reits E, Neefjes J. Trends Immunol. 37 724-737 (2016)
  8. Human leukocyte Antigen-DM polymorphisms in autoimmune diseases. Alvaro-Benito M, Morrison E, Wieczorek M, Sticht J, Freund C. Open Biol 6 (2016)
  9. A step-by-step overview of the dynamic process of epitope selection by major histocompatibility complex class II for presentation to helper T cells. Sadegh-Nasseri S. F1000Res 5 (2016)
  10. Mechanistic understanding and significance of small peptides interaction with MHC class II molecules for therapeutic applications. Afridi S, Hoessli DC, Hameed MW. Immunol. Rev. 272 151-168 (2016)
  11. Recent advances in sortase-catalyzed ligation methodology. Antos JM, Truttmann MC, Ploegh HL. Curr. Opin. Struct. Biol. 38 111-118 (2016)
  12. The melting pot of the MHC II peptidome. Stern LJ, Santambrogio L. Curr. Opin. Immunol. 40 70-77 (2016)
  13. Determinants of immunodominance for CD4 T cells. Kim A, Sadegh-Nasseri S. Curr. Opin. Immunol. 34 9-15 (2015)
  14. Stable mammalian producer cell lines for structural biology. Büssow K. Curr. Opin. Struct. Biol. 32 81-90 (2015)
  15. Chemical biology of antigen presentation by MHC molecules. van Kasteren SI, Overkleeft H, Ovaa H, Neefjes J. Curr. Opin. Immunol. 26 21-31 (2014)
  16. Measurement of Peptide Binding to MHC Class II Molecules by Fluorescence Polarization. Yin L, Stern LJ. Curr Protoc Immunol 106 5.10.1-12 (2014)
  17. Mechanisms of peptide repertoire selection by HLA-DM. Pos W, Sethi DK, Wucherpfennig KW. Trends Immunol. 34 495-501 (2013)
  18. HLA-DO and Its Role in MHC Class II Antigen Presentation. Poluektov YO, Kim A, Sadegh-Nasseri S. Front Immunol 4 260 (2013)
  19. A peptide's perspective on antigen presentation to the immune system. Neefjes J, Ovaa H. Nat. Chem. Biol. 9 769-775 (2013)
  20. Toward a Network Model of MHC Class II-Restricted Antigen Processing. Miller MA, Ganesan AP, Eisenlohr LC. Front Immunol 4 464 (2013)
  21. Inhibition of HLA-DM Mediated MHC Class II Peptide Loading by HLA-DO Promotes Self Tolerance. Denzin LK. Front Immunol 4 465 (2013)

Articles citing this publication (24)

  1. Common variants in the HLA-DQ region confer susceptibility to idiopathic achalasia. Gockel I, Becker J, Wouters MM, Niebisch S, Gockel HR, Hess T, Ramonet D, Zimmermann J, Vigo AG, Trynka G, de León AR, de la Serna JP, Urcelay E, Kumar V, Franke L, Westra HJ, Drescher D, Kneist W, Marquardt JU, Galle PR, Mattheisen M, Annese V, Latiano A, Fumagalli U, Laghi L, Cuomo R, Sarnelli G, Müller M, Eckardt AJ, Tack J, Hoffmann P, Herms S, Mangold E, Heilmann S, Kiesslich R, von Rahden BH, Allescher HD, Schulz HG, Wijmenga C, Heneka MT, Lang H, Hopfner KP, Nöthen MM, Boeckxstaens GE, de Bakker PI, Knapp M, Schumacher J. Nat. Genet. 46 901-904 (2014)
  2. Comprehensive analysis of MHC class II genes in teleost fish genomes reveals dispensability of the peptide-loading DM system in a large part of vertebrates. Dijkstra JM, Grimholt U, Leong J, Koop BF, Hashimoto K. BMC Evol. Biol. 13 260 (2013)
  3. HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis. Meza-Romero R, Benedek G, Yu X, Mooney JL, Dahan R, Duvshani N, Bucala R, Offner H, Reiter Y, Burrows GG, Vandenbark AA. J. Immunol. 192 4164-4173 (2014)
  4. Re-Directing CD4(+) T Cell Responses with the Flanking Residues of MHC Class II-Bound Peptides: The Core is Not Enough. Holland CJ, Cole DK, Godkin A. Front Immunol 4 172 (2013)
  5. Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide. Yin L, Trenh P, Guce A, Wieczorek M, Lange S, Sticht J, Jiang W, Bylsma M, Mellins ED, Freund C, Stern LJ. J. Biol. Chem. 289 23449-23464 (2014)
  6. Selector function of MHC I molecules is determined by protein plasticity. Bailey A, Dalchau N, Carter R, Emmott S, Phillips A, Werner JM, Elliott T. Sci Rep 5 14928 (2015)
  7. Divergent paths for the selection of immunodominant epitopes from distinct antigenic sources. Kim A, Hartman IZ, Poore B, Boronina T, Cole RN, Song N, Ciudad MT, Caspi RR, Jaraquemada D, Sadegh-Nasseri S. Nat Commun 5 5369 (2014)
  8. HLA-DO as the optimizer of epitope selection for MHC class II antigen presentation. Poluektov YO, Kim A, Hartman IZ, Sadegh-Nasseri S. PLoS ONE 8 e71228 (2013)
  9. Crossreactivity of a human autoimmune TCR is dominated by a single TCR loop. Sethi DK, Gordo S, Schubert DA, Wucherpfennig KW. Nat Commun 4 2623 (2013)
  10. IMPIPS: the immune protection-inducing protein structure concept in the search for steric-electron and topochemical principles for complete fully-protective chemically synthesised vaccine development. Patarroyo ME, Bermúdez A, Alba MP, Vanegas M, Moreno-Vranich A, Poloche LA, Patarroyo MA. PLoS ONE 10 e0123249 (2015)
  11. The Thermodynamic Mechanism of Peptide-MHC Class II Complex Formation Is a Determinant of Susceptibility to HLA-DM. Ferrante A, Templeton M, Hoffman M, Castellini MJ. J. Immunol. 195 1251-1261 (2015)
  12. Coupling between side chain interactions and binding pocket flexibility in HLA-B*44:02 molecules investigated by molecular dynamics simulations. Ostermeir K, Springer S, Zacharias M. Mol. Immunol. 63 312-319 (2015)
  13. Dipeptides catalyze rapid peptide exchange on MHC class I molecules. Saini SK, Schuster H, Ramnarayan VR, Rammensee HG, Stevanović S, Springer S. Proc. Natl. Acad. Sci. U.S.A. 112 202-207 (2015)
  14. Disruption of hydrogen bonds between major histocompatibility complex class II and the peptide N-terminus is not sufficient to form a human leukocyte antigen-DM receptive state of major histocompatibility complex class II. Schulze MS, Anders AK, Sethi DK, Call MJ. PLoS ONE 8 e69228 (2013)
  15. MHC class II complexes sample intermediate states along the peptide exchange pathway. Wieczorek M, Sticht J, Stolzenberg S, Günther S, Wehmeyer C, El Habre Z, Álvaro-Benito M, Noé F, Freund C. Nat Commun 7 13224 (2016)
  16. pH-susceptibility of HLA-DO tunes DO/DM ratios to regulate HLA-DM catalytic activity. Jiang W, Strohman MJ, Somasundaram S, Ayyangar S, Hou T, Wang N, Mellins ED. Sci Rep 5 17333 (2015)
  17. Evaluating the Role of HLA-DM in MHC Class II-Peptide Association Reactions. Yin L, Maben ZJ, Becerra A, Stern LJ. J. Immunol. 195 706-716 (2015)
  18. A novel method to measure HLA-DM-susceptibility of peptides bound to MHC class II molecules based on peptide binding competition assay and differential IC(50) determination. Yin L, Stern LJ. J. Immunol. Methods 406 21-33 (2014)
  19. Type 1 diabetes associated HLA-DQ2 and DQ8 molecules are relatively resistant to HLA-DM mediated release of invariant chain-derived CLIP peptides. Zhou Z, Reyes-Vargas E, Escobar H, Rudd B, Rockwood AL, Delgado JC, He X, Jensen PE. Eur. J. Immunol. 46 834-845 (2016)
  20. The MHC class II cofactor HLA-DM interacts with Ig in B cells. Macmillan H, Strohman MJ, Ayyangar S, Jiang W, Rajasekaran N, Spura A, Hessell AJ, Madec AM, Mellins ED. J. Immunol. 193 2641-2650 (2014)
  21. An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses. Parra-López CA, Bernal-Estévez D, Yin L, Vargas LE, Pulido-Calixto C, Salazar LM, Calvo-Calle JM, Stern LJ. PLoS ONE 9 e100639 (2014)
  22. Single-molecule motions of MHC class II rely on bound peptides. Kozono H, Matsushita Y, Ogawa N, Kozono Y, Miyabe T, Sekiguchi H, Ichiyanagi K, Okimoto N, Taiji M, Kanagawa O, Sasaki YC. Biophys. J. 108 350-359 (2015)
  23. Modeling Functional Motions of Biological Systems by Customized Natural Moves. Demharter S, Knapp B, Deane CM, Minary P. Biophys. J. 111 710-721 (2016)
  24. Peptidomic analysis of type 1 diabetes associated HLA-DQ molecules and the impact of HLA-DM on peptide repertoire editing. Zhou Z, Reyes-Vargas E, Escobar H, Chang KY, Barker AP, Rockwood AL, Delgado JC, He X, Jensen PE. Eur. J. Immunol. 47 314-326 (2017)